Swedish Orphan Biovitrum initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Swedish Orphan Biovitrum (BIOVF) with a Buy rating and SEK 530 price target Sobi is a profitable, cash-generative rare-disease biopharma company that the firm says is “compelling for capitalizing on pipeline-driven upside without taking single-binary, loss-making biotech risk.” The firm’s price target implies about 20% upside from the current share price, the analyst noted.